Javelin Pharmaceuticals, Inc. (AMEX: JAV - News) announced today that its CEO, Martin J. Driscoll, and Stephen J. Tulipano, CPA, CFO, will host a conference call to discuss the Company's quarterly results for the period ending March 31, 2008. The call will be held Wednesday, May 14, 2008 at 8:30 a.m. EDT.

The Company invites all interested parties to participate. The call will be web cast and accessible live through the following URL: http://ir.javelinpharmaceuticals.com/events.cfm. The call will be archived on the Company's website www.javelinpharmaceuticals.com.

CONFERENCE CALL ALERT

Javelin Pharmaceuticals, Inc. Q1 2008 Earnings Call

Date: May 14, 2008

Time: 8:30 a.m. E.D.T.

Please dial: (877) 604-9667 or International (719) 325-4895

About Javelin Pharmaceuticals, Inc.

Javelin Pharmaceuticals, Inc. (Amex: JAV - News), a leading developer and marketer of specialty pharmaceutical products for pain management, has received commitments from selected investors to purchase up to 11,450,000 shares of its common stock at a purchase price of $2.41 per share.

The purpose of the offering is to enhance our balance sheet as we proceed in our ongoing partnership discussions.

Certain officers and directors of Javelin will participate in this offering.

The closing of the offering is expected to take place on May 13, 2008, subject to customary closing conditions. The total number of shares to be sold in the offering are up to 11,450,000 with the gross proceeds of up to $27.6 million. The company estimates that net proceeds from the offering will be approximately $25.7 million, after deducting placement agent fees and estimated offering expenses.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News), announced today that it has fully enrolled its Phase II clinical trial of Curaxin CBLC102 in advanced, hormone-refractory (androgen independent) prostate cancer.

This open label trial is evaluating the safety and efficacy of Curaxin CBLC102 for use in treating patients with hormone-refractory metastatic prostate cancer. Curaxins have multiple mechanisms of action, including simultaneous activation of p53 and inhibition of NF-kappaB, which are frequently deregulated in cancer. Compounds that target p53 or NF-kappaB independently have been validated as cancer therapies; however, Curaxins are the only compounds currently known to CBLI that simultaneously target both pathways.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that Buyins.net initiated coverage on the Company after releasing the latest short sale data through May 2008.

The Buyins.net report stated that the total aggregate number of CBLI shares shorted between July 2006 and May 2008 is approximately 2.5 million shares. The report also stated that the CBLI SqueezeTrigger price of $7.41 is the volume weighted average short price of all short selling in CBLI.

Milestone Payments slated for reduction from $25 Million to $7 Million, Royalties from 10-12% to 4%

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News), today announced an agreement with BioAxone Therapeutic, Inc., of Montreal, Canada, whereby, upon payment by Alseres of an option fee of $7 million on or before October 27, 2008, Alseres may exercise an option to amend the Company's Cethrin License Agreement.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Pursuant to the option agreement, the pre-commercial milestone payments in the amended license agreement will be reduced from $25 million to $7 million payable on or before December 31, 2009. In addition, the sales-based royalties in the amended license agreement will be reduced from 10-12% to 4% for spinal cord injury and 1% for all other indications. Finally, the amended license agreement will eliminate all development milestones related to Cethrin.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News) today announced that the Company will participate in a panel entitled "Traumatic Brain and Spinal Cord Injury" at the Neurotech Industry Investing & Partnering Conference in Boston, MA, Thursday, May 8, 2008. The session will focus on emerging treatments of major traumatic injuries to the Central Nervous System (CNS). The event is the premier partnering and investing conference for the segment of the healthcare sector focused on neurological technologies.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) announced today that the Company has been featured in "Gene Marcial's 7 Commandments of Stock Investing," recently published by FT Press. Gene Marcial is a senior writer and columnist at BusinessWeek where he writes the column "Inside Wall Street."

Cleveland BioLabs was cited as one of "several little-known biotechs that have outscored their peers" under the chapter titled, "Commandment 6: Don't Fear The Unknown" of "Gene Marcial's 7 Commandments of Stock Investing." The chapter includes a brief summary by the author of Cleveland BioLabs' history and stock price from its IPO in July 2006 through early 2008.

Cleveland BioLabs, Inc. (NasdaqGM:CBLI - News) today announced that Chief Executive Officer and President, Michael Fonstein, Ph.D. and Chief Scientific Officer, Andrei Gudkov, Ph.D, D. Sci. shared 2008 highlights and milestones at the Company's annual meeting today.

Dr. Fonstein reviewed several of the Company's recent achievements including:

By Lynne Taylor

The US Food and Drug Administration will never have sufficient resources to be “the quality-control unit of the world,” and drugmakers will have to assume more responsibility for the quality of their products, a senior agency official has told US legislators.

The FDA is not the industry’s quality system, and the agency is holding companies accountable, Janet Woodcock, director of FDA’s Center for Drug Evaluation and Research, warned after addressing a hearing convened on April 24 by Democratic Senator Edward Kennedy, chairman of the Senate Education, Labor, Health and Pensions (HELP) Committee to discuss the contaminated heparin supply. “Any legislative fixes that do not address quality by design will fail,” she added.

WHO:	Rhonda Greenapple, MSPH, President of Reimbursement Intelligence and Warren Dodge, President of Oncology Metrics
WHAT:	ASCO Breakfast Session
WHERE:	The Matterhorn Room, located on the 42nd Floor., Swissotel Chicago, 323 E. Wacker Drive, Chicago, IL 60601
WHEN:	Monday, June 2nd, 6:30 a.m. – 7:30 a.m.

Until recently, oncology treatment decisions were exempt from health plan interference. With multiple early stage products entering the same category, premium pricing will be a challenge as payors increase their management of oncology products and costs shift for oncology patients.

Source: Science Blog

A newly created microbe produces cellulose that can be turned into ethanol and other biofuels, report scientists from The University of Texas at Austin who say the microbe could provide a significant portion of the nation’s transportation fuel if production can be scaled up.

Along with cellulose, the cyanobacteria developed by Professor R. Malcolm Brown Jr. and Dr. David Nobles Jr. secrete glucose and sucrose. These simple sugars are the major sources used to produce ethanol.

“The cyanobacterium is potentially a very inexpensive source for sugars to use for ethanol and designer fuels,” says Nobles, a research associate in the Section of Microbiology and Molecular Genetics.

Cleveland BioLabs, Inc. hosted a conference call today recapping recent achievements, as well as providing an update on the Company's development strategy and timeline.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic Foundation, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Research Radiobiology Institute.

By Ann Fernholm, Chronicle Staff Writer

The Food and Drug Administration is poised to throw its support behind a powerful new method of predicting the safety of experimental drugs, a step that could help pharmaceutical companies bring treatments to market more quickly - and reduce patients' risk.

The process being considered uses seven indicators - known as biomarkers - that signal kidney injury when found in the urine of test subjects.

"Today, the FDA gives approval for a new drug or device, but there has previously been no way to obtain approval for a new and better way to test a drug for its safety," said Raymond Woosley, president and CEO of the nonprofit Critical Path Institute, which is working with the FDA to safely speed drug development.

Competitive Technologies, Inc. (AMEX:CTT - News) held its annual meeting of shareholders today at the American Stock Exchange in New York City. John B. Nano, CTT's Chairman, President and CEO discussed the company's performance and its portfolio of technologies. The full slide presentation is available under Investors on the CTT website: http://www.competitivetech.net.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE - News) announced today that seven sites for the first stage of the ALTROPANE® Parkinson's or Essential Tremor - 2 (POET-2) Phase III clinical trial program are now open for patient enrollment. ALTROPANE molecular imaging agent is an investigational, diagnostic drug developed by Alseres to enable doctors to distinguish Parkinsonian Syndromes from non-Parkinsonian Syndromes in patients with tremor.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Alzheimer's experts have cautiously welcomed a revolutionary American treatment which is being used to help patients.

Alzheimer's disease (AD), also called Alzheimer disease or simply Alzheimer's, is the most common cause of dementia, afflicting 24 million people worldwide. Alzheimer's is a degenerative and terminal disease for which there is currently no known cure. In its most common form, it occurs in people over 65 years old although a less-prevalent early-onset form also exists. The disease can begin many years before it is eventually diagnosed. In its early stages, short-term memory loss is the most common symptom, often initially thought to be caused by aging or stress by the sufferer.

The Upcoming Era of Nanomedicine: A Briefing
Source: Drug Delivery Technology Magazine, April 2008

By: Bhupendra.G.Prajapati, MPharm; Jayvadan K. Patel, PhD; Vishnu M. Patel, PhD; and Krunal V. Prajapati

An increasingly diverse library of devices and technologies are used to aid drug targeting and delivery. The technologies include natural vectors (antibody and protein carriers, recombinant proteins, liposomes, and viruses), pseudo-synthetic vectors (polymercoated liposomes, polymerantibody hybrids), and synthetic vectors (polymer conjugates, polymeric micelles, and nanoparticles). The concepts of antibody-conjugates, liposomes, nanoparticles, and polymer-conjugates were born in the 1970s. Nanomedicine is beginning to emerge from research in nanotechnology.

Javelin Pharmaceuticals, Inc. (Amex: JAV - News), a leading developer and marketer of specialty pharmaceutical products for pain management, has appointed John C. Taylor as Vice President, Business Development. Mr. Taylor will report to Javelin’s recently appointed CEO Martin J. Driscoll and will be responsible for daily execution of Javelin’s global partnership initiatives for its late stage product pipeline.

“I have placed a high priority on Business Development initiatives as a strategic element of Javelin’s new commercialization strategy. Our first commercial partnership will be structured to accelerate the market uptake for our brand, reduce our exposure to early commercialization risk, and augment our growth capital while providing future upside. John will play an essential role in assisting us as we complete this effort,” said Martin Driscoll, Chief Executive Officer.

"NOV-002, a Glutathione Disulfide Mimetic, as a Modulator of Cellular Redox Balance"

Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Novelos’ peer reviewed article, based on the collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), has been published in Cancer Research 68: (8) April 15, 2008. This article describes findings in cellular and animal model systems that demonstrate the ability of NOV-002 to influence redox balance in and around cells, resulting in a constellation of effects on redox-sensitive cell processes and functions. NOV-002 is the subject of an ongoing pivotal Phase 3 trial for non-small cell lung cancer under a Special Protocol Assessment (SPA) and Fast Track, and is in Phase 2 trials for other oncology indications.

"NOV-002, a Glutathione Disulfide Mimetic, is a Pleiotropic Modulator of Cellular Redox Balance"

Novelos Therapeutics, Inc. (OTCBB: NVLT - News), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, announced that today Novelos is presenting a scientific poster, based on the collaboration with Dr. Kenneth Tew and Dr. Danyelle Townsend of the Medical University of South Carolina (MUSC), at the ongoing American Association for Cancer Research (AACR) annual meeting in San Diego, CA. This presentation will describe findings in cellular and animal model systems that demonstrate the ability of NOV-002 to influence redox balance in and around cells, resulting in a constellation of effects on redox-sensitive cell processes and functions.